Home » Stocks » OPT

Opthea Limited (OPT)

Stock Price: $8.39 USD -0.25 (-2.89%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 339.27M
Revenue (ttm) 228,254
Net Income (ttm) n/a
Shares Out 42.21M
EPS (ttm) n/a
PE Ratio n/a
Forward PE 6.73
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $8.39
Previous Close $8.64
Change ($) -0.25
Change (%) -2.89%
Day's Open 8.50
Day's Range 7.95 - 8.71
Day's Volume 5,053
52-Week Range 7.95 - 14.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

MELBOURNE, Australia, April 06, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT) advises that Mr Michael Tonroe has resigned as Company Secretary and Chief Financial Officer (CFO) of the Co...

1 month ago - GlobeNewsWire

MELBOURNE, Australia, March 31, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progres...

1 month ago - GlobeNewsWire

MELBOURNE, Australia, March 15, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progre...

1 month ago - GlobeNewsWire

MELBOURNE, Australia, March 10, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT, Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progre...

1 month ago - GlobeNewsWire

MELBOURNE, Australia, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progres...

2 months ago - GlobeNewsWire

MELBOURNE, Australia, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT, Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progres...

2 months ago - GlobeNewsWire

Nine IPOs and five SPACs went public this past week, and one IPO postponed.

Other stocks mentioned: ALGS, ARRY, CDAK, EBC, PRAX, SPEL, TARS
6 months ago - Seeking Alpha

MELBOURNE, Australia, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT, Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progres...

6 months ago - GlobeNewsWire

Opthea, an Australian clinical stage biotech company, is going public to help fund its Phase 3 trials and take on two large biotech companies. About Opthea: The main area of focus for Opthea Ltd (NASDAQ...

6 months ago - Benzinga

Opthea has filed proposed terms to raise capital from a U.S. IPO.

6 months ago - Seeking Alpha

About OPT

Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3 for the treatment of wet age-related macular degeneration and diabetic macular edema. The c... [Read more...]

Industry
Biotechnology
IPO Date
Oct 16, 2020
CEO
Megan Baldwin
Country
Australia
Stock Exchange
NASDAQ
Ticker Symbol
OPT
Full Company Profile

Financial Performance

In 2020, Opthea's revenue was 87,075, a decrease of -45.26% compared to the previous year's 159,064. Losses were -16.53 million, -20.95% less than in 2019.

Financial numbers in millions AUD.
Financial Statements